A defective switching off of the immune response is involved in several autoimmune diseases. This switching off involves Fas-mediated apoptosis, perforin-mediated fratricide of activated lymphocytes, and the suppressive activity of regulatory T (Treg) cells. These mechanisms are altered in autoimmune lymphoproliferative syndrome that often displays autoimmune thrombocytopenia. The aim of this research was to evaluate these mechanisms in adult patients with primary immune thrombocytopenia (ITP), compared with healthy controls. The results show that a substantial subgroup of the ITP patients displayed a defective Fas function; most of them displayed decreased Fas expression in T cells activated in vitro. Moreover, ITP patients displayed an increased frequency of rare missense variations of the PRF1 gene and decreased levels of Treg. Immunological analysis showed that levels of Interleukin (IL)10 and IL17 were decreased and marginal zone B cells were increased. Moreover, myeloid and plasmacytoid dendritic cells were decreased in ITP patients. In conclusion, in adult ITP patients, several mechanisms involved in shutting off the immune response are defective and several immunological parameters are dysregulated; these alterations may play a role in the clinical heterogeneity of the disease.
Summary
A defective switching off of the immune response is involved in several autoimmune diseases. This switching off involves Fas-mediated apoptosis, perforin-mediated fratricide of activated lymphocytes, and the suppressive activity of regulatory T (Treg) cells. These mechanisms are altered in autoimmune lymphoproliferative syndrome that often displays autoimmune thrombocytopenia. The aim of this research was to evaluate these mechanisms in adult patients with primary immune thrombocytopenia (ITP), compared with healthy controls. The results show that a substantial subgroup of the ITP patients displayed a defective Fas function; most of them displayed decreased Fas expression in T cells activated in vitro. Moreover, ITP patients displayed an increased frequency of rare missense variations of the PRF1 gene and decreased levels of Treg. Immunological analysis showed that levels of Interleukin (IL)10 and IL17 were decreased and marginal zone B cells were increased. Moreover, myeloid and plasmacytoid dendritic cells were decreased in ITP patients. In conclusion, in adult ITP patients, several mechanisms involved in shutting off the immune response are defective and several immunological parameters are dysregulated; these alterations may play a role in the clinical heterogeneity of the disease.
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including T helper (Th) 1 and cytotoxic T cell (CTL)-mediated platelet destruction. These different disease mechanisms may be involved in the existence of different forms of ITP and responses to treatment (K€ uhne, 2013; Ji et al, 2014) . Immune thrombocytopenia is more frequent in children where it generally has an acute onset, is associated with viral infection and displays spontaneous recovery. In contrast, ITP in adults more frequently has an unexplained aetiology, chronic course and heterogeneous behaviour, ranging from mild asymptomatic thrombocytopenia not requiring treatment to severe thrombocytopenia, high risk of bleeding and refractoriness to several therapeutic approaches.
Fas is expressed by activated lymphocytes and induces their apoptosis upon binding to Fas ligand (FasL, also termed FASLG) expressed by several cell types. Functional defects of mechanisms involved in switching off the immune response have been detected in several autoimmune diseases. They include defects of Fas-mediated apoptosis and perforinmediated fratricide of activated lymphocytes. Moreover, many autoimmune diseases display decreased levels of regulatory T (Treg) cells, which have also been detected in ITP (Comi et al, 2000 (Comi et al, , 2009 DeFranco et al, 2001; Dianzani et al, 2003; Chiocchetti et al, 2005 Chiocchetti et al, , 2010 Cappellano et al, 2008; Orilieri et al, 2008; Buttini et al, 2015) .
A possible involvement of Fas in ITP is suggested by the role played by this molecule in autoimmune lymphoproliferative syndrome (ALPS), as chronic autoimmune thrombocytopenia is a frequent manifestation in ALPS, a rare disease caused by genetic defects of Fas function. ALPS is characterized by accumulation of polyclonal lymphocytes in the lymph nodes and the spleen with expansion of T cell receptor (TCR) ab-positive CD4/CD8 double-negative (DN) T cells and frequent development of autoimmune manifestations mainly involving blood cells. Most patients carry a heterozygous mutation in the FAS gene that can be either inherited or, less frequently, somatic. Generally, ALPS is diagnosed in childhood, but it may rarely develop also in adulthood possibly because of additional somatic genetic events (Fisher et al, 1995; Dianzani et al, 1997; Campagnoli et al, 2006; Oliveira et al, 2010; Rieux-Laucat et al, 1995; Lambotte et al, 2013) .
In subjects carrying a defective Fas function, the development of ALPS may be favoured by variations in genes such as secreted phosphoprotein 1 (SPP1, also known as OPN) and perforin (PRF1), working as risk factors by affecting other mechanisms involved in shutting off the immune response (Comi et al, 2000 (Comi et al, , 2009 DeFranco et al, 2001; Chiocchetti et al, 2004 Chiocchetti et al, , 2005 Chiocchetti et al, , 2010 Clementi et al, 2004 Clementi et al, , 2006 Cappellano et al, 2008; Orilieri et al, 2008; Buttini et al, 2015) .
Osteopontin (also termed secreted phosphoprotein 1, SPP1) is a proinflammatory cytokine that can inhibit lymphocyte apoptosis both directly and indirectly by inducing the production of other anti-apoptotic factors such as Tissue Inhibitor Metalloproteinases-1 and Interleukin (IL) 17 (Gravallese, 2003; Boggio et al, 2010 Boggio et al, , 2014 . Variants of SPP1 marked by the +1239A>C (rs9138) single nucleotide polymorphism (SNP) and causing production of increased amounts of osteopontin increase the risk of development of ALPS .
Perforin is one of the main tools used by cytotoxic cells to kill their target cells and is involved in shutting off the immune response by fratricide of activated immune cells (Vogelsang et al, 2010) . Biallelic loss of function mutations of PRF1 causes familial haemophagocytic lymphohistiocytosis, an immunodeficiency with defective function of CTL and natural killer (NK) cells (Vogelsang et al, 2010) . Moreover, heterozygous missense variants of PRF1 increase the risk of development of ALPS (Clementi et al, 2004 (Clementi et al, , 2006 .
Intriguingly, defective Fas function and the SPP1 or PRF1 variants are also displayed by subsets of patients with other autoimmune diseases such as multiple sclerosis, type-I diabetes mellitus and chronic inflammatory demyelinating polyneuropathy (Comi et al, 2000 (Comi et al, , 2009 DeFranco et al, 2001; Dianzani et al, 2003; Chiocchetti et al, 2005 Chiocchetti et al, , 2010 Cappellano et al, 2008; Orilieri et al, 2008; Buttini et al, 2015) .
The aim of our research was to analyse the possible pathogenic effects of these factors in the development of ITP in adults and to look for correlations with immunological and clinical parameters. The results showed that a substantial subgroup of the ITP patients displayed a defective function of Fas without FAS gene mutations. Moreover, the ITP patients displayed an increased frequency of variations of the PRF1 gene. Immunological analyses showed that ITP patients displayed decreased levels of Treg, IL10, and IL17, whereas marginal zone (MZ) B cells were increased. Moreover, myeloid and plasmacytoid dendritic cells (mDC and pDC, respectively, were decreased in ITP patients. However, the Fas and perforin defects did not display correlations with these immunological alterations.
Methods

Patients
This multicentre observational study involved eight Italian centres. To be included into the study, patients had to be ≥18 years and have a diagnosis of primary ITP according to the guidelines of the American Society of Hematology (Neunert et al, 2011) . Centres were asked to include consecutive patients either with newly diagnosed or previously diagnosed ITP. Results were compared with those observed in a cohort of healthy controls (HC) matched for ethnic origin and age. Written informed consent was obtained from patients and HC. The study was approved by the local ethical committee (N. 64/2010) and conducted in accordance with the Declaration of Helsinki. The Fas function assay and genetic analyses were made on peripheral blood (PB) samples, collected at least 1 month after the end of the last treatment in previously diagnosed patients. Immunological analysis and 
Fas function analysis
Fas-induced cell death (FICD) was evaluated in activated T cells as previously reported (Dianzani et al, 1997) . Fas function was defined as defective when cell survival was >82% (the 95th percentile of data obtained from 100 HC). Fas expression was evaluated by immunofluorescence using a fluorescein isothiocyanate (FITC) anti-Fas monoclonal antibody (mAb) (BioLegend, San Diego, CA, USA) plus a phycoerythrin (PE) anti-TCR ab mAb (eBioscience, San Diego, CA, USA) on the same day of the FICD assay.
DNA amplification and sequence analysis
Genomic DNA was isolated from PB using standard methods. The +1239A>C SNP of SPP1 was typed as previously reported . Exons and intron-exon boundaries of PRF1 and FAS were amplified and sequenced on a 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Primers are available upon request. Cytokine secretion PBMC (1 9 10 5 ) were cultured for 5 d in the presence of anti-CD3 (1 lg/ml; OKT3 clone) and either B7h-Fc (5 lg/ ml; R&D Systems, Minneapolis, MN, USA) or B7Á1-Fc (5 lg/ml; R&D Systems). Moreover, cells were re-stimulated with Phorbol 12-myristate 13-acetate (PMA, 50 ng/ml; Sigma-Aldrich) plus Ionomycin (500 ng/ml; Sigma-Aldrich) for 5 h in the presence of brefeldin A (10 lg/ml; SigmaAldrich) for single cell analysis. IL17A and IL10 were measured by enzyme-linked immunosorbentassay (ELISA, R&D Systems) or by intracellular analysis in activated PBMC. Cells were permeabilized and stained with a PE anti-IL10 mAb (MiltenyiBiotec) and an APC anti-IL17A mAb (eBioscience) and analysed by flow cytometry.
Statistical analysis
The Mann-Whitney U-test and Fisher's Exact Test were used to compare data from patients and controls, applying the Bonferroni correction. The different clinical groups were compared using one-way ANOVA followed by Kruskal-Wallis with Dunn post-hoc analysis to analyse the absolute data, whereas Fisher's Exact Test with Bonferroni correction was used to compare the single patient analyses. Allele and genotype distributions were analysed using v 2 test with Yates's correction. All P values were 2-tailed, and the significance cut-off was P < 0Á05. The analysis was performed with GraphPad Instat software (GraphPad Software, San Diego, CA, USA).
Results
Patients
Between November 2010 and July 2013, 168 patients were analysed; 32 with newly diagnosed ITP and 136 with a previous diagnosis of ITP, respectively. The median age was 55 years and 58% were females. Patients were stratified into three clinical groups according to disease severity and responsiveness to therapy: (i) indolent ITP (N = 36), i.e. patients with asymptomatic ITP, platelet count >50 9 10 9 /l, who never necessitated anti-ITP treatment; (ii) sensitive ITP, i.e. patients who necessitated steroid (steroid sensitive, N = 44) or rituximab as second line therapy, (rituximab sensitive, N = 26) because of platelet count <20 9 10 9 /l and who displayed sustained response (platelet count >50 9 10 9 /l) for at least 6 months after the end of treatment; (iii) refractory ITP, i.e. patients who necessitated steroid (N = 85) or rituximab (N = 27) because of platelet count <20 9 10 9 /l and didn't satisfy the criteria for sustained response ( Table I) . Clinical analysis compared FICD in indolent patients, patients that were sensitive or refractory to steroids and patients sensitive or refractory to rituximab (Table II) . Results showed that FICD was higher in steroid-sensitive patients (61Á5%) than in rituximab-refractory patients (76Á2%, P < 0Á05). The proportion of patients displaying defective Fas function was not significantly different in these groups. DN T cell expansion was evaluated in all subjects (168 ITP patients and 100 HC), because it is associated with defective FICD in ALPS but not in other autoimmune diseases. Substantial differences of the proportions of these cells were not detected in the patients and the HC (Fig 1C) or in the patients with a new and a previous diagnosis [median (IQR): 0Á7% (0Á5-1Á1) vs. 0Á7% (0Á5-1Á1)]. Analysis at single patient level showed that expansion of these cells was more (Table II) but did not detect significant differences (data not shown). FAS was sequenced in the 33 ITP patients with defective Fas function and/or expansion of DN T cells but no mutations were identified (data not shown).
Analysis of Fas function
Analysis of PRF1 and SPP1 gene variants
We sequenced the PRF1 gene and typed the SPP1 + 1239A>C SNP in the group of patients with a previous diagnosis.
PRF1 sequences were obtained in 121 patients, including 19 patients with defective Fas function and six patients with DN T cell expansion, and 268 HC. Twenty patients (16Á5%) and 24 HC (9%) were found to carry missense variations. In particular, 14/121 patients (1 homozygous, 13 heterozygous) and 23/268 HC (all heterozygous) carried the A91V amino acid substitution that was relatively frequent in the control population, whereas six patients and 1 HC carried rare variations (all heterozygous) showing allelic frequencies of <1% in the control population. Among the rare amino acid substitutions, three patients and 1 HC carried N252S, two patients R28C and one patient R385W. The overall genotype frequency of all these variations was higher in the patients than in HC [16Á5% vs. 9%; odds ratio (OR) = 2 (95% confidence interval (CI): 1Á06-3Á2), P = 0Á044]. Moreover, the overall genotype frequency of the rare variations was strikingly higher in the patients than in HC (5% vs. 0Á37%; OR = 13Á3 (1Á61-109Á2), P = 0Á006), whereas that of A91V was not significantly different in patients and controls (11Á6% vs. 8Á6%) (Table III) . Among the six patients carrying the rare missense variations, 3 (one carrying R28C, two N252S) also displayed defective Fas function (50%), whereas none displayed DN T cell expansion. Among those carrying A91V, 2 also displayed defective Fas function (14%) whereas one displayed DN T cell expansion (7%).
SPP1 type was obtained in 96 ITP patients, including 13 patients with defective Fas function and five patients with DN T cell expansion, and 158 HC. The results displayed a similar genotype distribution in patients and HC (ITP versus HC: AA 52% vs. 51%; AC 41% vs. 39%; CC 7Á3% vs. 10%).
No differences in the frequency of PRF1 or SPP1 variations were found between the different clinical groups of patients (data not shown). ITP, immune thrombocytopenia; FICD, Fas-induced cell death; DN, double negative; IQR, interquartile range. *P < 0Á04; significantly different from steroid sensitive; one-way ANOVA followed by Kruskal-Wallis with Dunn post-hoc analysis. (Fig 2) , and NKT cells (0Á04% vs. 0Á09%; data not shown).
We assessed secretion of IL10 and IL17A, produced by Treg and Th17 cells respectively, in PBMC. Both ELISA and intracellular immunofluorescent analyses showed that IL10 and IL17A secretion was significantly lower in the patients than in HC (Fig 3) .
The patients displaying either defective Fas function, expanded DN T cells or carrying the rare PRF1 variants had similar results to those of the whole cohort for all these immunological parameters.
Clinical analysis compared these immunological parameters in indolent patients, patients sensitive or refractory to steroids and patients sensitive or refractory to rituximab, but no significant differences were detected (data not shown).
Discussion
Our research shows that ITP patients may display several defects of the immune response switching off system, including defective Fas function, increased frequency of missense variations of PRF1 and decreased Treg cells, together with other immunological alterations involving several immune cell subsets.
A key finding was that about 20% of the ITP patients had a decreased Fas function that displayed a similarly severe defect to that previously reported in ALPS patients (i.e. >82% of cell survival upon Fas triggering) (Dianzani et al, 1997) . Moreover, DN T cells, a typical feature of ALPS, were expanded in about 5% of the whole ITP patients and about 10% of those displaying defective Fas function. Only three patients (1Á8%) displayed both defective Fas function and DN T cells expansion, which are two diagnostic criteria required for ALPS diagnosis. The diagnosis of ALPS did not fit with any patient, as none of the ITP patients displayed signs of lymphoproliferation, i.e. splenomegaly and/or lymphoadenomegaly, which is a required diagnostic criterion for ALPS diagnosis (Oliveira et al, 2010) but it is an exclusion criterion for ITP diagnosis (Neunert et al, 2011) . These data are in line with those reported for other autoimmune diseases in which a proportion of patients display a defective Fas function in the absence of DN T cell expansion and signs of lymphoproliferation (Comi et al, 2000 (Comi et al, , 2009 DeFranco et al, 2001; Dianzani et al, 2003) . Another similarity with these autoimmune diseases is that the defective Fas function of ITP patients is not due to mutations of FAS, which, on the contrary, are the most frequent cause of ALPS. However, the Fas defect may be partly ascribed to unknown factors decreasing Fas expression, which was substantially low in activated T cells derived from ITP patients but in the normal range for other autoimmune diseases. Given that the decreased Fas expression was detected in most ITP patients, including many displaying normal function in vitro, it is possible that the impact of decreased Fas function is largely underestimated in ITP by the FICD assay. The defective Fas expression, in fact, may be functionally relevant in vivo also in subjects who display normal Fas function in vitro, considering that the in vitro assay is performed in conditions of maximal triggering of Fas which may not reproduce limiting conditions of low levels of FasL in vivo. These Fas defects seem to mark a difference between adult and paediatric ITP, as the latter have been reported to display normal Fas function and increased Fas expression (Dianzani et al, 1997) . By contrast, variable proportions of children with Evans syndrome, with least 2 autoimmune cytopenias, may display both decreased Fas function and DN T cell expansion (Dianzani et al, 1997; Chang-Lin et al, 2007; Aladjidi et al, 2011; Seif et al, 2010) . In this work, we did not assess the expression levels of FasL, which may further influence Fas function. However, FasL expression did not influence our FICD analysis in which Fas was triggered using an anti-Fas mAb.
The clinical analysis of our ITP patients depicts a trend of progressive increase of the proportion of subjects with defective Fas function from the clinically mildest group, i.e. indolent patients (11Á8%), to progressively worst groups, i.e. those sensitive (17Á1%) or refractory (21Á9%) to steroids and those sensitive (27%) or refractory (34Á6%) to rituximab. Moreover, it showed that the FICD was significantly different between patients sensitive to steroid and those refractory to rituximab. It is unlikely that this trend was ascribable to therapies, as it was also displayed by patients at diagnosis (data not shown). Dual resistance to rituximab and steroids is not a feature of ALPS that is highly sensitive to both drugs (Teachey, 2012) . These data are in line with our previous reports showing that defective Fas function correlates with disease aggressive courses in multiple sclerosis, type-I diabetes mellitus, and chronic inflammatory demyelinating polyneuropathy (Comi et al, 2000 (Comi et al, , 2009 DeFranco et al, 2001; Dianzani et al, 2003) .
In ALPS, defective Fas function partly depends on increased IL17 production inhibiting FICD (Boggio et al, 2014) but this seems not to be true in the case of ITP patients, since their T cells displayed decreased IL17 production, as detected by the same methods previously used in ALPS. These data disagree with some reports showing increased IL17 production in ITP, but heterogeneous results have been obtained using different methodological approaches (Zhang et al, 2009; Sollazzo et al, 2011; Guo et al, 2009; Talaat et al, 2014) .
In some patients, variations of PRF1 that decrease the function of perforin, which is involved in both defence from viral infections and shutting off the immune response (Vogelsang et al, 2010) , may contribute to disease onset. The most intriguing result was the increased frequency of rare missense variations, which were detected in 5% of the patients and whose presence increased the risk of ITP development by about 14-fold. Moreover, the frequency of these variations increased to 10% in the case of the patients displaying defective Fas function and, conversely, 50% of the patients with these variations displayed defective Fas function. These data suggest not only that missense PRF1 variations favour ITP development, as suggested for other autoimmune diseases, but also that the defects of Fas and perforin function may cooperate in favouring ITP development, as previously suggested for ALPS (Clementi et al, 2004 (Clementi et al, , 2006 . All of the missense variations detected in our ITP patients may have had an impact on perforin function and/or expression. N252S has been described in ALPS and type 1 diabetes (Clementi et al, 2006; Orilieri et al, 2008) ; its functional significance is debated (RieuxLaucat et al, 2005) , but it has been associated with decreased NK activity in childhood . R28C has been described in juvenile rheumatoid arthritis and melanoma and has been shown to decrease perforin function (Trapani et al, 2013; Vastert et al, 2010) . R385W has been described in Patients with lymphoma or chronic inflammatory demyelinating polyneuropathy (Ding & Yang, 2013; Buttini et al, 2015) ; its functional effect is not known but it has been predicted to be deleterious by several in silico analyses. A second point is that several patients carried A91V (one in homozygosis), which decreases perforin expression and function and has been associated with lymphomas and several autoimmune diseases (Clementi et al, 2006; Muralitharan et al, 2006; Cappellano et al, 2008; Trapani et al, 2013) , but this variation, which is relatively frequent in the general population, seems not to be involved in ITP because its frequency was not increased in our patients. Moreover, ITP development seems not to be influenced by the SPP1 variations involved in the development of ALPS and other autoimmune diseases (Chiocchetti et al, , 2005 .
Given that defective function of Fas and perforin have been associated with development of lymphomas and monoclonal expansion of B and T cells have been reported in ITP patients (Roark et al, 2002; Shimomura et al, 1996; Ware & Howard, 1993) , we evaluated B cell receptor and TCR monoclonality in a group of ITP patients. Results detected clonal expansion of T cells in a small minority (about 5%) of ITP patients but not in those displaying defective Fas function or PRF1 variations or DN T cell expansion (data not shown).
ITP patients displayed a decreased number of Treg cells, which may contribute to the disease, as Treg cells are involved in the switching-off of the immune response together with Fas and perforin. These data are in line with several reports of decreased Treg cells in ITP patients, and other autoimmune diseases including ALPS (Boggio et al, 2014; Hua et al, 2014; Grant et al, 2015) . Moreover, they are in line with the decreased production of IL10 displayed by ITP since Treg cells can produce IL10 (Grant et al, 2015) . The decreased production of IL10 marks a difference between ITP and ALPS, where IL10 levels are increased (Lopatin et al, 2001) . Another difference between ITP and ALPS is that MZ B cells are increased in the former and decreased in the latter (Rensing-Ehl et al, 2010) . However, the increased levels of MZ B cells in ITP is in line with the notion that these are prone to autoimmunity and play a role in several experimental models of lupus (Sang et al, 2014) .
Finally, circulating mDC and pDC are decreased in ITP patients, which might be ascribed to increased recruitment of these cells from the blood to the tissues and suggests their role in the disease. In line with these data, dendritic cells of ITP show a greater capacity to present platelet antigens to T cells (Catani et al, 2006) . Moreover, pDC and mDC levels have been reported to be decreased also in Sj€ ogren syndrome (Vastert et al, 2010) .
In conclusion, this study has shown that several mechanisms involved in shutting off the immune response are defective in adult ITP patients and may play a role in the onset and chronic evolution of the disease. They include the defective function of Fas, perforin, and Treg cells that also have been reported in ALPS, but no patient fulfilled the diagnostic criteria of ALPS (Fig 4) . Moreover, ITP patients displayed several other immunological alterations, but the defective Fas function and the PRF1 variations did not correlate with them. The clinical analysis of our patients suggests that some of these defects may play a role in the clinical heterogeneity of the disease. Author contributions E.Boggio., C.L.G., G.C., N.C., and M.C. performed the experiments; F.Z., D.R., G.G., N.V., S.C., M.L., A.T., S.P., E.T., and E.Beggiato recruited the patients; U.D., R.F., A.C., C.C., and F.Z. designed the study, wrote the manuscript and analysed the data.
